Corpus ID: 12540787

Novel mutein of tumor necrosis factor alpha (F4614) with reduced hypotensive effect.

@article{Shikama1995NovelMO,
  title={Novel mutein of tumor necrosis factor alpha (F4614) with reduced hypotensive effect.},
  author={H. Shikama and K. Miyata and N. Sakae and Y. Mitsuishi and K. Nishimura and K. Kuroda and M. Kato},
  journal={Journal of interferon \& cytokine research : the official journal of the International Society for Interferon and Cytokine Research},
  year={1995},
  volume={15 8},
  pages={
          677-84
        }
}
  • H. Shikama, K. Miyata, +4 authors M. Kato
  • Published 1995
  • Medicine
  • Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
To eliminate systemic toxicity, including the hypotension associated with human tumor necrosis factor alpha (TNF-alpha), we constructed mutant proteins (muteins) by mean of genetic engineering. A novel mutein, F4614, containing mutations of 5Thr-->Gly and 6Pro-->Asp, which resulted in the introduction of cell-adhesive Arg-Gly-Asp and 29Arg-->Val, had remarkably reduced hypotensive effects and lower lethality. We present evidence that the Arg-->Val mutation at position 29 is largely responsible… Expand
Integrin Targeted Delivery of Chemotherapeutics
TLDR
This review highlights the recent advances in integrin targeted delivery of chemotherapeutic agents with emphasis on target of integrin αvβ3, and describes the considerations for the design of the diverse RGD peptide-chemotherapeutics conjugates and their major applications. Expand
New ways in RGD-peptide mediated drug targeting to angiogenic endothelium : On the nature of drugs, linkers, and carriers.
TLDR
This thesis aimed at improving the tissue distribution of anti-inflammatory, anti-angiogenic or antivascular therapeutics by redirecting such compounds to activated and angiogenic endothelial cells, finding αvβ3-integrin is an optimal target receptor for an intracellular drug targeting approach. Expand
RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature.
TLDR
This review will summarize the structural requirements for RGD-peptides andRGD-mimetics as ligands for alphavbeta3 and show how they have been introduced in the various types of constructs by chemical and recombinant techniques. Expand